Today’s Top Three in Pharma 063009

Ouch. Jury returns $ 1.67 billion verdict against Abbott (patent infringement vs J&J) – A U.S. federal jury returned a $1.67 billion verdict against Abbott Laboratories in a patent suit brought by Johnson & Johnson related to arthritis treatments, the drug companies said on Monday. An Abbott spokesman said the company would appeal the verdict [...]

Read Full Post »

Today’s Top Three in Pharma 062909

I think it’s going to be more than 3 today…! Does Lantus (Sanofi drug for diabetes) increase cancer risk? Takeda‘s alogliptin (new diabetes treatment) – FDA says, more info please. European Medicines Agency approves a variety pack of new drugs and expanded indications. Here’s the rundown. Drug companies increasingly using Medical Science liaisons. In my [...]

Read Full Post »

Today’s Top Three in Pharma 062309

A 9th PML case with Tysabri since reintroduction – Biotechnology company Biogen Idec Inc. said late Friday a ninth Tysabri patient developed a potentially deadly brain infection since the drug was reintroduced to the market in 2006. The drug, which treats multiple sclerosis, was pulled from the market in 2005 following occurrences of a rare, [...]

Read Full Post »

Today’s Top Three in Pharma 062209

THE BIG DEAL – Pharma and the U.S. government come up with drug discount agreement. More detail here. New Forest Labs pneumonia drug reaches goals – Forest Laboratories Inc said on Friday its experimental antibiotic proved to be at least as effective as an older medicine in pneumonia patients, reaching its main goal in two [...]

Read Full Post »

Fill in the Blank: What’s your _____ Strategy?

I’m prepping to meet tomorrow with a biotech client about potential usage of social media. But in looking over the client’s website, and thinking about pharma SM issues, and reviewing my “Ten Consulting Questions”, I had to chuckle. We’ll really be brainstorming a communications strategy. Not a single one of the 10 main issues necessitates [...]

Read Full Post »

Today’s Top Three in Pharma 061809

Medtronic, a doctor, transparency, and 800K – Remember that former Army doctor accused of faking data in a published study that found positive results for a Medtronic product? Turns out, Medtronic paid him nearly $800,000 over the past three years. Here’s the report from this morning’s WSJ…more RA drug Mabthera: use early, use often – [...]

Read Full Post »

Today’s Top Three in Pharma 061709

Why are Doctors so down on Pharma? Only a tenth of prescriptions are truly “up for grabs”? Interesting analysis – Traditional promotion efforts, including details and sampling, can only affect about 10% of prescriptions, an IMS study found, suggesting that the bulk of promotion dollars is misplaced…more Another gout drug (this one from Savient Pharmaceuticals) [...]

Read Full Post »

A Bag o’ Pharma Marketing links

Over the span of days and weeks, an accumulation of various and sundry items piles up relating to pharma marketing. Sometimes, they just need a blog post mixed bag collection. Here it is. Could iPhones transform pharma marketing? (from Fierce Pharma blog) Why mobile marketing for pharma matters (from Pharma 2.0 blog). Internet advertising has [...]

Read Full Post »

Today’s Top Three in Pharma 061209

Cumberland Pharmaceuticals gets an injectable approved – Cumberland Pharmaceuticals (www.cumberlandpharma.com) today announced the U.S. Food and Drug Administration (FDA) has approved Caldolor(TM), an intravenous formulation of ibuprofen, through a priority review. Caldolor is the first and only injectable product approved for sale in the United States for the treatment of both pain and fever…more Pfizer‘s [...]

Read Full Post »

Today’s Top Three in Pharma 0605096

Pfizer‘s Chantix still getting the slow-burn investigation by the regulators – Federal regulators are still investigating the safety of Pfizer’s anti-smoking drug Chantix, a probe that began last year after thousands of patients reported blackouts and other problems…more Also, Pfizer at the forefront of the newest “Who wants to buy Elan??” rumors. Merck‘s experimental Phase [...]

Read Full Post »